With the current standard treatment of trastuzumab and pertuzumab for N1 HER2-overexpressing breast cancer, the therapeutic effect has approached that of the best luminal A type, further weakening the value of postoperative radiotherapy for N1 breast cancer. Here, ERBB2 is linked to breast carcinoma.